Earlier this month, healthcare artificial intelligence (AI) company Paige announced a new partnership with renowned technology giant, Microsoft.
Paige describes itself as a company at the forefront of technology and healthcare, especially in the field of cancer diagnostics and pathology. The company explains its mission: “Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare…[we strive] to transform cancer diagnostics. We make it possible not only to provide additional information from digital slides to help pathologists perform their diagnostic work efficiently and confidently, but also to go beyond by extracting novel insights from digital slides that can’t be seen by the naked eye. These unique tissue signatures have the potential to help guide treatment decisions and enable the development of novel biomarkers from tissues for diagnostic, pharmaceutical and life sciences companies.”
The company offers a variety of solutions. On the clinical front, Paige’s AI tools enable advanced diagnostics in the lab with computational pathology, which can be leveraged to identify complex tissue patterns. On the pharmaceutical front, the company’s tools offer new ways to identify and analyze tissue biomarkers, pushing forward diagnostic and predictive capabilities.
Given its new partnership with Microsoft, the goal will be to use the latter’s incredibly robust resources in healthcare and technology to further unlock value in Paige’s tools. Andy Moye, CEO of Paige explained: “In Microsoft, we’ve really found a partner that shares our vision in how healthcare is going to be transformed … For us, the vision we talked to Microsoft about is, how do we help create the digitization of pathology? How do we ensure that these tools are being used to get better patient care, to get better patient outcomes?”